A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia (NAVIGATE-AD)

I7X-MC-LLCF -

The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer's disease (AD) dementia.

Trial Summary

Age Range
55 - 85 years
Conditions the trial is for
What the trial is testing?
Could I receive a Placebo?
Yes
Enrollment Goal
316
Trial Dates
Jun 16, 2016 - Jul 2, 2018
How long will I be in the trial?
Your participation could last approximately 1 year and include 19 visits to the study center.
Trial Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.